Ladenburg Thalmann analyst Aydin Huseynov initiated coverage of NeuroBo Pharmaceuticals with a Buy rating and $6 price target.
Published first on TheFly
Ladenburg Thalmann analyst Aydin Huseynov initiated coverage of NeuroBo Pharmaceuticals with a Buy rating and $6 price target.
Published first on TheFly